for people ages 18 years and up (full criteria)
at San Francisco, California
study started
estimated completion
Toby Maurer



To determine the safety of escalating doses of Tc 99m tilmanocept in HIV (human immunodeficiency virus) subjects with confirmed KS.

Official Title

An Evaluation of the Safety of Escalating Doses of Tc 99m Tilmanocept by Intravenous (IV) Injection in Human Immunodeficiency Virus (HIV) Subjects Diagnosed With Kaposi Sarcoma (KS)


This is a prospective, single-center, open-label, within-subject study of intravenously injected Tc 99m tilmanocept in the localization and detection of cutaneous and non-cutaneous KS tumor(s) in subjects with biopsy-confirmed KS. Six IV doses (µg/mCi) of tilmanocept will be evaluated in cohort groups.

This study is designed to evaluate the safety and tolerability of escalating doses of Tc 99m tilmanocept. Whole body planar as well as SPECT/CT imaging will be performed to provide greater resolution of areas of Tc 99m tilmanocept localization. A biopsy of a non-visceral KS lesion will be taken to correlate pathology with Tc 99m tilmanocept localization.

This study is designed to evaluate the use of Tc 99m tilmanocept as an imaging agent in HIV-positive subjects with known KS by evaluating localization in known and unknown cutaneous and non-cutaneous lesions.


Kaposi SarcomaHIV InfectionsKaposi Sarcoma, KS, HIVSarcomaSarcoma, KaposiTc99m-tilmanocept


You can join if…

Open to people ages 18 years and up

  1. The subject has provided written informed consent with HIPAA authorization before the initiation of any study-related procedures.
  2. The subject is at least 18 years of age at the time of consent.
  3. The subject is HIV positive.
  4. The subject has a biopsy-confirmed diagnosis of KS and is classified into one of the categories below:
  5. Confirmed cutaneous KS/oral lesions without edema.
  6. Confirmed cutaneous KS/oral lesions with edema.
  7. Confirmed cutaneous KS/oral lesions with or without edema and suspected non-cutaneous KS due to clinical symptomology or confirmed non-cutaneous KS lesion(s).

You CAN'T join if...

  1. The subject is pregnant or lactating.
  2. The subject has received chemotherapy or radiation therapy to KS sites within six weeks of enrollment.
  3. The subject has known sensitivity to dextran.
  4. The subject has received an investigational product within 30 days prior to the Tc 99m tilmanocept administration.
  5. The subject has received any radiopharmaceutical within 7 days prior to the administration of Tc 99m tilmanocept.
  6. Any condition that, in the clinical judgment of the treating physician, is likely to prevent the subject from complying with any aspect of the protocol or that may put the subject at unacceptable risk.


  • Zuckerberg San Francisco General Hospitalaccepting new patients
    San FranciscoCalifornia94143United States

Lead Scientist

  • Toby Maurer
    Authored (or co-authored) 61 research publications


accepting new patients
Start Date
Completion Date
Navidea Biopharmaceuticals
Phase 1
Study Type
Last Updated